Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 400
- Registration Number
- NCT00671008
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 293
- Registration Number
- NCT00669864
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
Phase 1
Terminated
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: NNC 0070-0002-0182Drug: placebo
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 101
- Registration Number
- NCT00665665
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Madison, Wisconsin, United States
Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: isophane human insulin
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8125
- Registration Number
- NCT00665808
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1569
- Registration Number
- NCT00665093
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of
Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 402
- Registration Number
- NCT00660374
Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 57610
- Registration Number
- NCT00659282
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study to Evaluate the Safety of Levemir® in Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51170
- Registration Number
- NCT00659295
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2289
- Registration Number
- NCT00657930
Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 699
- Registration Number
- NCT00658099
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Bucharest, Romania
© Copyright 2025. All Rights Reserved by MedPath